Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)

CANDLE: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Once Monthly Oral Ibrexafungerp for Prevention of Recurrent Vulvovaginal Candidiasis (VVC)

All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)